Dr. Black on Sequencing of Immunotherapy in Bladder Cancer

Peter Black, MD
Published: Tuesday, Jun 20, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses sequencing of immunotherapy for patients with bladder cancer.

Bladder cancer now has many different therapies which has made the sequencing of treatments a question that needs to be answered, explains Black.

Currently, patients with metastatic bladder cancer would receive chemotherapy and then a checkpoint inhibitor, such as durvalumab (Imfinzi). If patients are cisplatin ineligible, atezolizumab (Tecentriq) is approved in that setting, states Black.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses sequencing of immunotherapy for patients with bladder cancer.

Bladder cancer now has many different therapies which has made the sequencing of treatments a question that needs to be answered, explains Black.

Currently, patients with metastatic bladder cancer would receive chemotherapy and then a checkpoint inhibitor, such as durvalumab (Imfinzi). If patients are cisplatin ineligible, atezolizumab (Tecentriq) is approved in that setting, states Black.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x